

CorMedix Inc.  
Form 8-K  
October 27, 2014

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 27, 2014

CORMEDIX INC.  
(Exact Name of Registrant as Specified in  
Charter)

|  |  |  |
|--|--|--|
| Delaware<br>(State or Other<br>Jurisdiction of<br>Incorporation) | 001-34673<br>(Commission File<br>Number) | 20-5894890<br>(IRS Employer<br>Identification No.) |
|--|--|--|

745 Rt. 202-206,  
Suite 303,  
Bridgewater, NJ 08807  
(Address of  
Principal  
Executive  
Offices) (Zip  
Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed  
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01. Other Events.

On October 27, 2014, CorMedix issued a press release announcing approval from the United States Food and Drug Administration to initiate a clinical trial for Neutrolin® in the U.S.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit<br>No. | Description |
|----------------|-------------|
|----------------|-------------|

|             |                                       |
|-------------|---------------------------------------|
| <u>99.1</u> | Press release dated October 27, 2014. |
|-------------|---------------------------------------|

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: October 27, 2014

By:

/s/ Randy Milby

Name: Randy Milby

Title: Chief Executive Officer